Wang, G et al. Neuropsychiatr Dis Treat. 2020;16(16):221-234
Mrazek DA et al. Psychiatr Serv. 2014;65(8):977-987.
Amos T et al. J Clin Psychiatr. 2018;79(2):17m11725.
Souery D et al. J Clin Psychiatry. 2007;68:1062–70.
Lopez Munoz et al. Curr Pharm Des. 2009; 15 (14):1563-86.
A long-term comparison of esketamine nasal spray versus quetiapine extended release, both in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor, in participants with treatment resistant major depressive disorder (ESCAPE-TRD). NCT 04338321. Clinicaltrials.gov 2023. Available at: https://clinicaltrials.gov/ct2/show/NCT04338321?term=escape-trd&draw=2&rank=1 [Accessed November 2023].
Heerlein, K et al. Most Common Treatments in Patients with Treatment Resistant Depression Based on European Cohort Study Real-World Evidence. Presented at ISPOR 2022, November 6-9. Poster HSD28.
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.